{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:20:28Z","timestamp":1793974828303,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jhep.2022.11.019","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T02:19:41Z","timestamp":1669774781000},"page":"658-662","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Treatment of portal hypertension in patients with HCC in the era of Baveno VII"],"prefix":"10.1016","volume":"78","author":[{"given":"Dominique","family":"Thabut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jhep.2022.11.019_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII -\u00a0renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2022.11.019_bib2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2009.01.014","article-title":"Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis","volume":"50","author":"Ripoll","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2022.11.019_bib3","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2022.11.019_bib4","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/j.1572-0241.2004.40336.x","article-title":"Outcomes of patients with hepatocellular carcinoma presenting with variceal bleeding","volume":"99","author":"Lang","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2022.11.019_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"10181","key":"10.1016\/j.jhep.2022.11.019_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jhep.2022.11.019_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/liv.13611","article-title":"Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions","volume":"38","author":"Grgurevic","year":"2018","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhep.2022.11.019_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The platelet lifeline to cancer: challenges and opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jhep.2022.11.019_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101785","article-title":"Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: a \u201cmenage \u00e0 trois\u201d!","volume":"46","author":"Campion","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2022.11.019_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/apt.16490","article-title":"Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States","volume":"54","author":"Wijarnpreecha","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2022.11.019_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/00365521.2020.1762919","article-title":"Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients","volume":"55","author":"Udumyan","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2022.11.019_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.dld.2019.06.019","article-title":"Ulcer bleeding after band ligation of esophageal varices: risk factors and prognosis","volume":"52","author":"Due\u00f1as","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.jhep.2022.11.019_bib13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/hep.26629","article-title":"Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study","volume":"58","author":"Ripoll","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhep.2022.11.019_bib14","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses\u2026","volume":"41","author":"Allaire","year":"2021","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.jhep.2022.11.019_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101790","article-title":"TIPS for patients with early HCC: a bridge to liver transplantation","volume":"46","author":"Larrey","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2022.11.019_bib16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s00270-013-0698-8","article-title":"Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt","volume":"36","author":"Kuo","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.jhep.2022.11.019_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jvir.2020.09.007","article-title":"Safety and efficacy of segmental yttrium-90 radioembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt creation","volume":"32","author":"Gordon","year":"2021","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"20","key":"10.1016\/j.jhep.2022.11.019_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jhep.2022.11.019_bib19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2011-0465","article-title":"Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma","volume":"17","author":"Boige","year":"2012","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.jhep.2022.11.019_bib20","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2022.11.019_bib21","doi-asserted-by":"crossref","unstructured":"Larrey E, Campion B, Evain M, Sultanik P, Blaise L, Giudicelli H, et al. A history of variceal bleeding is associated with further bleeding under Atezolizumab-Bevacizumab in patients with HCC. Liver Int 2022.Dec;42(12):2843-2854.","DOI":"10.1111\/liv.15458"},{"issue":"4","key":"10.1016\/j.jhep.2022.11.019_bib22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/hep.32468","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study","volume":"76","author":"D'Alessio","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2022.11.019_bib23","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.jhep.2022.11.019_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jhep.2022.11.019_bib25","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782203313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782203313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:33Z","timestamp":1759175313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782203313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S016882782203313X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.11.019","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of portal hypertension in patients with HCC in the era of Baveno VII","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}